Also in this playlist...
This transcript is automatically generated
Journal -- releasing its list of the top stock pickers on the street the best of all all this week we're bringing you the number one name in five different sectors.
Today's masters stock -- Michael King JA MP securities managing director and senior Biotech analyst.
His top pick last year.
Was up a hundred and it.
Well I do a lot of pride spent a lot of time big deep in the weeds in the science and I try to as accurately as possible.
-- market forecasts talked a lot of positions we.
As much as we can look at patient -- see what they're saying about the drugs.
And see if that's -- believable perspective to build and to move into the forecast and we try to be as accurate as possible and bring that back and see how it compares today's stock price and if it looks cheap.
We -- -- -- blogs it's it's really changing world because even just ten years ago that's probably didn't exist yeah you can actually just hear their response to it.
And how the drug is actually affecting their -- and they know a lot about what's going on too so I can educate yourself on other drugs lawyer finding out about the company follow.
Michael what other things that appeals to an investor like me likes the whole -- for what doesn't like to keep checking -- -- you have.
That have holding power that best that you -- -- hold for two were three years yes yeah absolutely I mean I think names that we currently have buy recommendations on the oncology space area had Celgene.
Let's let's get right today -- are all long term.
But let's deal with something like Celgene Celgene over twelve months has gone from 58 the public to share -- up to 131.
Does have one of these huge run ups right I would be worried if I was buying into it now -- -- whether it has the stamina to last another two.
It does coming just held a an analyst and investor meeting in new York and mapped out its.
Long term pipeline they're investing in all the right areas it's really quite remarkable how that company has transformed itself.
From a one drug company to a multi drug company -- -- billion dollar franchises.
Was investing for the period beyond.
Which is -- area that they've given formal guidance to you but you can see by the investments that they're making they're gonna be strong from seventeen -- -- on.
-- some horizon that you're looking at -- area pharmacy S also we host them many times all right program we can find them very innovative yes they just had up a recent well in December last year.
One of the fastest FDA approvals for I crusade which we think is going to be.
Significant blockbuster for them.
I'm -- been under a little bit of pressure from some worry worked warts were telling people take advantage of the current weakness we just had.
Dinner with them in new York and things are hitting on all cylinders there we like Gary -- very much.
-- again it's one of the few stocks -- by low right now it's at the low cycle of its twelve month period.
-- -- clicks yes Barbara six race had a -- I don't know if you put the date chart up but it had to jump of over 8% today right what's going on there and white alike well one of our competitors -- came around to the positive side that we've been following this company literally since 2009.
But how we think they're drug -- -- it is really going to be what does it do its four a number of different.
A blood cancers but the lead indication is for chronicling Pacific leukemia CLL its most common form of adult leukemia.
They will be on the market with their drug I've reviewed by the end of the year in at least one.
Indication and based on again patient blogs and position discussions I think once is drug gets approved in one indication.
It will be -- and many others.
Many of these biotechnology companies with some real forward thinkers who are leading them tend also partner with big pharmaceutical companies today then gets swallowed and is that opportunity lesson lesson when your example of -- had our ads going global on the world on -- so they don't need a marker of five all I think.
-- investors have woken up to that fact they are now you know it.
-- requesting that companies retain as much of that downstream value.
As they possibly can because -- company -- gotten I think it was not a lot smarter they used to have to rely on pharma companies now they can do these themselves.
And the benefit accrues to the company and its shareholders.
You are great at least right back wages hi Melissa yeah I agree anytime we see why that award as well deserved -- and restart Bernanke -- -- thank you thank you very much Michael networks.
Filter by section